Crescendo Biologics Strengthens its Management with the Appointment of Dr Pavel Pisa as Chief Medical Officer
Cambridge, UK, 11 September 2018 – Crescendo Biologics Ltd (Crescendo), the drug developer of novel,…
read more
Crescendo Biologics is developing two proprietary platforms for biological therapeutics from the Babraham Institute: ribosome display for the optimization of antibodies and a transgenic mouse which produces heavy chain only antibodies.
